InCarda Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InCarda Therapeutics, Inc.
Year Ahead Could Prove Rough For Private Biotech Financing
The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.
Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.
Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services
Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.
- Drug Delivery
- Other Names / Subsidiaries
- InCarda Therapeutics Australia Pty Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.